Other
First Line Therapy
0
Pipeline Programs↗
14
Active Trials↗
6
Companies Involved↗
First Line Therapy is an early-stage landscape with 0 programs across 6 companies. The most active players are Merck & Co., Pfizer, Bristol-Myers Squibb.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
56
clinical trials
Completed22 · 39%
Unknown status14 · 25%
Recruiting7 · 13%
Not yet recruiting4 · 7%
Terminated3 · 5%
Active, not recruiting2 · 4%
Other4 · 7%
Clinical Trials
Trial Activity
56 trials
First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy
Recruiting·—·Phase 2·NCT06667167·21 enrolled
Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China
Recruiting·—·Phase 2·NCT04857164·150 enrolled
QoL in mCRC Elderly Patients Receiving First-line Therapy Based on Simplified Geriatric Parameters.
Active, not recruiting·GERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT03828227·49 enrolled
Combination of Steroid and Humanized CD25 Monoclonal Antibody as First-line Therapy for aGVHD
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06473909·20 enrolled
An Exploratory Study of Lurbinectedin With Radiotherapy in Locally-advanced SCLC After First-line Therapy
Not yet recruiting·—·Phase 2·NCT06501976·9 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)